Back to discover
Drug

Rifampin

Established medicine
ClassBacterial DNA-directed RNA polymerase inhibitorResearchActive indication expansion
Also known as 3-(((4-Methyl-1-piperazinyl)imino)methyl)rifamycin SV, IsonaRif, RFP, Rifamate+7 more

3-(((4-Methyl-1-piperazinyl)imino)methyl)rifamycin SV, IsonaRif, RFP, Rifamate, Rifampicina, Rifampicine, Rifampicinum, Rifater, Rimactane, Rifadin, Rifampicin.

RxNorm9384ChEMBLCHEMBL374478ATCJ04AB02UNIIVJT6J7R4TR
3
Research papers
28
Active clinical trials
4
Protein targets
11
Regulatory events
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Plasma and Breastmilk Exposures to Antituberculosis Drugs in Breastfeeding Women: an Open-label, Randomized, Six-arm, Single-dose, Pharmacokinetic Study

Clinical trial2026-10-31Primary completion · ClinicalTrials.gov

An Open-Label Drug Interaction Clinical Study to Evaluate Itraconazole, Rifampin, Midazolam and SIM0270 in Chinese Healthy Adult Participants

Clinical trial2026-10-30Primary completion · ClinicalTrials.gov

Label change: RIFAMPIN (ANDA091181)

Regulatory2026-09-29FDA

Adjunctive Rifampin for the Treatment of Prosthetic Valve Endocarditis Due to S. Aureus (RIFA-SNAP)

Clinical trial2026-09-21Status changed to Terminated · ClinicalTrials.gov

Phase 2C Clinical Trial of Novel, Short-course Regimens for the Treatment of Pulmonary Tuberculosis: CRUSH-TB (Combination Regimens for Shortening TB Treatment)

Clinical trial2026-09-21Results expected Q4 2026 · ClinicalTrials.gov

IMPI-3 - A Randomized Controlled Trial of High vs. Standard Dose Rifampicin for Effusive Tuberculous Pericarditis

Clinical trial2026-09-01Status changed to Completed · ClinicalTrials.gov

Generic approval: RIFAMPIN (ANDA219918)

Regulatory2026-06-29FDA

Label change: RIFAMPIN (ANDA091181)

Regulatory2025-07-25FDA

Label change: RIFAMPIN (ANDA091181)

Regulatory2024-06-12FDA

Estimation of country-specific tuberculosis resistance antibiograms using pathogen genomics and machine learning.

Research2024-03-28BMJ global health

Potent twice-weekly rifapentine-containing regimens in murine tuberculosis.

Research2006-03-30American journal of respiratory and critical care medicine

Weekly moxifloxacin and rifapentine is more active than the denver regimen in murine tuberculosis.

Research2005-09-01American journal of respiratory and critical care medicine

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Rifampin
Aliases & brands
3-(((4-Methyl-1-piperazinyl)imino)methyl)rifamycin SVIsonaRifRFPRifamateRifampicinaRifampicineRifampicinumRifaterRimactaneRifadinRifampicin
RxNorm CUI
9384
ChEMBL ID
CHEMBL374478
ATC codes
J04AB02
UNII
VJT6J7R4TR
Primary mechanism
Bacterial DNA-directed RNA polymerase inhibitor
Regulatory jurisdictions
fda

Pharmacology & targets

4 targets

Known molecular targets and mechanisms supported by curated pharmacology databases.

DNA-directed RNA polymerase subunit beta
rpoB · P0A8V2
INHIBITORBacterial DNA-directed RNA polymerase inhibitor
DNA-directed RNA polymerase subunit alpha
rpoA · P0A7Z4
INHIBITORBacterial DNA-directed RNA polymerase inhibitor
DNA-directed RNA polymerase subunit beta'
rpoC · P0A8T7
INHIBITORBacterial DNA-directed RNA polymerase inhibitor
DNA-directed RNA polymerase subunit omega
rpoZ · P0A800
INHIBITORBacterial DNA-directed RNA polymerase inhibitor

Regulatory timeline

11 events

The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.

Earliest approval on record (generic/biosimilar)
2014-08-21
Latest approval
2026-06-29
Authorities
FDA
Total events
11
fdaU.S. Food and Drug Administration· 11 events
2026-09-29Label change
Label change: RIFAMPIN (ANDA091181)
Evidence ↗
2026-06-29Generic approvalMarket
Generic approval: RIFAMPIN (ANDA219918)
Evidence ↗
2025-07-25Label change
Label change: RIFAMPIN (ANDA091181)
Evidence ↗

Data from the U.S. Food and Drug Administration (U.S. Food and Drug Administration), public domain (CC0).

Clinical trials

195 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
195
registered trials across all phases
LATEST COMPLETION 2026
28
Active studies
24
Recruiting
46
Late-stage (III+)
142
Completed
25
Discontinued
PHASE DISTRIBUTIONn = 195
Early Phase 11Phase 1119Phase 1 / 21Phase 228Phase 2 / 33Phase 320Phase 412Phase N / A11

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

Short-term Antibiotic Therapy in Mycobacterium Avium Complex Pulmonary Disease

RecruitingPH IVBin Caon=1882028

Short-term Bactericidal Effect of Contezolid in Mycobacterium Avium Complex Pulmonary Disease

RecruitingPH IVBin Caon=1882027

Impact of LTBI Treatment on Glucose Tolerance and Chronic Inflammation

CompletedPH IVHerlev and Gentofte Hospitaln=322023

Epidemiology and Treatment of Small-colony Variant Staphylococcus Aureus in Cystic Fibrosis

WithdrawnPH IVJohns Hopkins University2021

Efficacy, Security, Adherence, Tolerability and Cost Effectiveness of Latent TB Treatment in Patients With TB/DM2

CompletedPH IVInstituto Nacional de Salud Publica, Mexicon=3962019

Recent completions

Trials that read out recently, adding to the completed evidence base.

Co-SAM: An Adaptive Multi-arm Trial to Improve Clinical Outcomes Among Children Recovering From Complicated Severe Acute Malnutrition

CompletedPH IIIQueen Mary University of Londonn=6742026

Evaluation of Drug-Drug Interactions Between CS0159 Tablets and Rifampicin/Itraconazole and the Effect of a High-Fat Meal on the Pharmacokinetic Characteristics of CS0159 Tablets in Healthy Adult Participants

CompletedPH ICascade Pharmaceuticals, Incn=322026

A Phase 2/3, Multicenter, Randomized, Open-label, Active-controlled Study to Evaluate the Efficacy and Safety of Bedaquiline Administered as Part of a Treatment Regimen With Clarithromycin and Ethambutol in Adult Patients With Treatment-refractory Mycobacterium Avium Complex-lung Disease (MAC-LD)

CompletedPH II/IIIJanssen Pharmaceutical K.K.n=1292025

A Phase 1, Open-Label, Single-Dose, Two-Period, Fixed Sequence, Crossover Study to Determine the Effect of Rifampin on the Pharmacokinetics of Divarasib in Healthy Subjects

CompletedPH IGenentech, Inc.n=182025

An Open-label Fixed Sequence Trial to Investigate the Potential Drug-drug Interaction When BI 907828 is Co-administered With an OATP1B1 and/or OATP1B3 Transporter Inhibitor or With a CYP3A4 Inhibitor in Patients With Various Solid Tumours

CompletedPH IBoehringer Ingelheimn=332025

2R2: Higher Dose Rifampin for 2 Months vs Standard Dose Rifampin for Latent TB: a 3-arm Randomized Trial.

CompletedPH IIMcGill University Health Centre/Research Institute of the McGill University Health Centren=1,3682024

Research activity

3 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Publications over time
2005–2024
Most influential

Potent twice-weekly rifapentine-containing regimens in murine tuberculosis.

American journal of respiratory and critical care medicine · 2006 · 60 cites

Weekly moxifloxacin and rifapentine is more active than the denver regimen in murine tuberculosis.

American journal of respiratory and critical care medicine · 2005 · 43 cites

Estimation of country-specific tuberculosis resistance antibiograms using pathogen genomics and machine learning.

BMJ global health · 2024 · 4 cites
Recent papers

Estimation of country-specific tuberculosis resistance antibiograms using pathogen genomics and machine learning.

BMJ global health · 2024 · 4 cites

Potent twice-weekly rifapentine-containing regimens in murine tuberculosis.

American journal of respiratory and critical care medicine · 2006 · 60 cites

Weekly moxifloxacin and rifapentine is more active than the denver regimen in murine tuberculosis.

American journal of respiratory and critical care medicine · 2005 · 43 cites
Major research themes2
Antitubercular Agents1Tuberculosis, Multidrug-Resistant1
Journals, researchers & institutions
Top journals
  • American journal of respiratory and critical care medicine2
  • BMJ global health1
Leading researchers
  • Bishai WR2
  • Grosset JH2
  • Nuermberger EL2
  • Peloquin CA2
  • Rosenthal IM2
  • Tyagi S2
  • Vernon AA2
  • Williams K2
Leading institutions
free-text, unnormalised
  • Center for Tuberculosis Research2
  • Boston Children's Hospital1
  • Center for Computational Biomedicine1
  • Clinical Microbiology and Infectious Diseases1
  • Dana-Farber Cancer Institute1
  • Harvard Medical School1

Related drugs

2 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

Ethionamide

Studied across the same disease area as Rifampin in the shared literature.

1 shared disease1 shared paper
Isoniazid

Studied across the same disease area as Rifampin in the shared literature.

1 shared disease1 shared paper
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials
  • Regulatory event sources are credited in the Regulatory Timeline above.